DALLAS, January 18, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2014" to its store. This report provides an overview of the Dry (Atrophic) Macular Degeneration's therapeutic pipeline.
The report "Dry (Atrophic) Macular Degeneration Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scopeof Dry (Atrophic) Macular Degeneration Pipeline Review, H2 2014 covers: a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Dry (Atrophic) Macular Degeneration and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Dry (Atrophic) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=248277. (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Dry (Atrophic) Macular Degeneration Pipeline Review, H2 2014 report include Acucela Inc., Alimera Sciences, Inc., Bioheart, Inc., Catalyst Biosciences, Inc., Cell Cure Neurosciences, Ltd., Eleven Biotherapeutics Inc., EyeCyte, Inc., Foamix Pharmaceuticals Ltd., Genentech, Inc., GlaxoSmithKline plc, Icon Bioscience, Inc., Inotek Pharmaceuticals Corporation, MacuCLEAR, Inc., Neurotech Pharmaceuticals, Inc., Ocata Therapeutics, Inc., Ophthotech Corp., pSivida Corp., Tacere Therapeutics, Inc.
Reasons to buy Dry (Atrophic) Macular Degeneration Pipeline Review, H2 2014 research report:
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Global Markets Direct report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Explore more reports on the Ophthalmology therapeutics market athttp://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics .
About Us:
RnRMarketResearch.com is a digital library of 500,000+ syndicated market research reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
Connect with Us:
G+ / Google Plus:https://plus.google.com/104156468549256253075/posts
Twitter:https://twitter.com/RnRMR
Facebook:https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds:http://www.rnrmarketresearch.com/feed
